Carole Soussain

Summary

Country: France

Publications

  1. doi Primary central nervous system lymphoma: an update
    Carole Soussain
    Hematology Centre René Huguenin, Saint Cloud, France
    Curr Opin Oncol 21:550-8. 2009
  2. doi Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire
    Carole Soussain
    Department of Hematology, Biostatistics Unit, Centre Rene Huguenin, Saint Cloud, France
    J Clin Oncol 26:2512-8. 2008
  3. pmc Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases
    Carole Soussain
    Department of Hematology, Hôpital René Huguenin, Institut Curie, Saint Cloud, France
    Haematologica 97:1751-6. 2012
  4. ncbi [Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma]
    Carole Soussain
    Service d Hematologie Clinique, CHG, Meaux
    Bull Cancer 91:189-92. 2004
  5. ncbi Chemotherapy delivery issues in central nervous system malignancy: a reality check
    Leslie L Muldoon
    Department of Neurology, Oregon Health and Science University, Portland, and the Veterans Administration Medical Center, OR 97239 3098, USA
    J Clin Oncol 25:2295-305. 2007
  6. ncbi Delivery of chemotherapy and antibodies across the blood-brain barrier and the role of chemoprotection, in primary and metastatic brain tumors: report of the Eleventh Annual Blood-Brain Barrier Consortium meeting
    Nancy D Doolittle
    Department of Neurology, Oregon Health and Science University, 3181 S W Sam Jackson Park Road L603, Portland, OR 97239 3098, USA
    J Neurooncol 81:81-91. 2007
  7. ncbi New treatment approaches in primary central nervous system lymphoma
    Carole Soussain
    Hematologie, Centre Hospitalier Général de Meaux, 6 8 rue Saint Fiacre, BP 218, 77104 Meaux Cedex, France
    Hematol Oncol Clin North Am 19:719-28, vii. 2005
  8. ncbi A multicenter study of gemcitabine-containing regimen in relapsed or refractory Hodgkin's lymphoma patients
    Patricia Validire
    Department of Clinical Hematology, Institut Curie, Paris, France
    Anticancer Drugs 19:309-15. 2008
  9. ncbi Recent advances in primary CNS lymphoma
    Khe Hoang-Xuan
    Department of Neurology, Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, Paris 75651 Cedex 13, France
    Curr Opin Oncol 16:601-6. 2004
  10. ncbi Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report
    Nancy D Doolittle
    Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
    Blood 111:1085-93. 2008

Collaborators

Detail Information

Publications10

  1. doi Primary central nervous system lymphoma: an update
    Carole Soussain
    Hematology Centre René Huguenin, Saint Cloud, France
    Curr Opin Oncol 21:550-8. 2009
    ..The purpose of the present review is to present an overview of the recent findings in diagnostic procedures, treatment outcomes and biological advances in primary central nervous system lymphoma (PCNSL)...
  2. doi Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Française de Greffe de Moëlle Osseuse-Thérapie Cellulaire
    Carole Soussain
    Department of Hematology, Biostatistics Unit, Centre Rene Huguenin, Saint Cloud, France
    J Clin Oncol 26:2512-8. 2008
    ....
  3. pmc Intensive chemotherapy with thiotepa, busulfan and cyclophosphamide and hematopoietic stem cell rescue in relapsed or refractory primary central nervous system lymphoma and intraocular lymphoma: a retrospective study of 79 cases
    Carole Soussain
    Department of Hematology, Hôpital René Huguenin, Institut Curie, Saint Cloud, France
    Haematologica 97:1751-6. 2012
    ....
  4. ncbi [Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma]
    Carole Soussain
    Service d Hematologie Clinique, CHG, Meaux
    Bull Cancer 91:189-92. 2004
    ..Seven patients had neurologic adverse events during the entire procedure. With a median follow up of 6.2 years, the median overall survival is 91 months, and the median survival after intensive chemotherapy has not been reached...
  5. ncbi Chemotherapy delivery issues in central nervous system malignancy: a reality check
    Leslie L Muldoon
    Department of Neurology, Oregon Health and Science University, Portland, and the Veterans Administration Medical Center, OR 97239 3098, USA
    J Clin Oncol 25:2295-305. 2007
    ..This review assesses the current state of knowledge regarding preclinical and clinical pharmacology for brain tumor chemotherapy and evaluates relevant brain tumor pharmacology studies before October 2006...
  6. ncbi Delivery of chemotherapy and antibodies across the blood-brain barrier and the role of chemoprotection, in primary and metastatic brain tumors: report of the Eleventh Annual Blood-Brain Barrier Consortium meeting
    Nancy D Doolittle
    Department of Neurology, Oregon Health and Science University, 3181 S W Sam Jackson Park Road L603, Portland, OR 97239 3098, USA
    J Neurooncol 81:81-91. 2007
    ....
  7. ncbi New treatment approaches in primary central nervous system lymphoma
    Carole Soussain
    Hematologie, Centre Hospitalier Général de Meaux, 6 8 rue Saint Fiacre, BP 218, 77104 Meaux Cedex, France
    Hematol Oncol Clin North Am 19:719-28, vii. 2005
    ..This article discusses the rationale and results of these innovative approaches...
  8. ncbi A multicenter study of gemcitabine-containing regimen in relapsed or refractory Hodgkin's lymphoma patients
    Patricia Validire
    Department of Clinical Hematology, Institut Curie, Paris, France
    Anticancer Drugs 19:309-15. 2008
    ..5 g/dl. This study demonstrated the limited efficacy of gemcitabine-containing regimen in heavily pretreated HL patients...
  9. ncbi Recent advances in primary CNS lymphoma
    Khe Hoang-Xuan
    Department of Neurology, Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, Paris 75651 Cedex 13, France
    Curr Opin Oncol 16:601-6. 2004
    ..This review highlights the recent advances in the pathogenesis and treatment of primary CNS lymphoma (PCNSL) in the immunocompetent population...
  10. ncbi Brain parenchyma involvement as isolated central nervous system relapse of systemic non-Hodgkin lymphoma: an International Primary CNS Lymphoma Collaborative Group report
    Nancy D Doolittle
    Department of Neurology, Oregon Health and Science University, Portland, OR 97239, USA
    Blood 111:1085-93. 2008
    ..Our results suggest systemic methotrexate is the optimal treatment for isolated CNS relapse involving the brain parenchyma. Long-term survival is possible in some patients...